Uncategorized
FDA, CDC call for pause of chikungunya shot rollout in older adults
Ixchiq vaccine, chikungunya, safety concerns, older adults, FDA, CDC, pause recommendation, adverse events
Accelerating Clinical Trial Excellence: A Seamless IRB & IBC Collaboration
Clinical trials, IRB, IBC, collaboration, streamlined review, multi-institutional research, regulatory efficiency, research acceleration, biosafety, human subject protection
Trump signs sweeping executive order to cut US drug prices by ‘up to 90%’
Prices, HHS, United States, Transplant Registry Unified Management Program, Policy
Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures
Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology
AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients
Imfinzi, Clinical Trials, high-risk, expansion, Malignant neoplasm of urinary bladder
Revolutions KRAS drugs appear competitive in several lung cancer settings
KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines
Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis
Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment
FDA Delays Continue as Regulator Misses Review Date for GSKs Nucala
United States Food and Drug Administration, Nucala, Chronic Obstructive Airway Disease, GSK ‘s, Target, delays, PDUFA
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
Vaccines, Urinary hesitation, Offit, cynicism, Misinformation, Immune response, Paul Offit, mandates
Vinay Prasads FDA Appointment Anything but Status Quo
United States Food and Drug Administration, Appointments, Vaccines, Prasad, Prasad ‘s, Anything, Status Quo